Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E118.73 EPS (ttm)0.65 Insider Own0.50% Shs Outstand180.73M Perf Week-2.17%
Market Cap14.36B Forward P/E154.75 EPS next Y0.50 Insider Trans-22.35% Shs Float180.30M Perf Month1.24%
Income122.30M PEG2.50 EPS next Q1.20 Inst Own99.30% Short Float6.48% Perf Quarter-37.48%
Sales1.85B P/S7.77 EPS this Y69.50% Inst Trans0.45% Short Ratio4.92 Perf Half Y-20.85%
Book/sh17.91 P/B4.33 EPS next Y-88.02% ROA2.50% Target Price110.48 Perf Year11.63%
Cash/sh7.45 P/C10.40 EPS next 5Y47.54% ROE3.90% 52W Range67.10 - 131.95 Perf YTD-8.30%
Dividend- P/FCF- EPS past 5Y32.00% ROI-0.70% 52W High-41.24% Beta0.69
Dividend %- Quick Ratio2.30 Sales past 5Y17.90% Gross Margin78.20% 52W Low15.54% ATR2.35
Employees3001 Current Ratio3.30 Sales Q/Q10.80% Oper. Margin3.20% RSI (14)49.88 Volatility2.89% 2.77%
OptionableYes Debt/Eq0.45 EPS Q/Q22.80% Profit Margin6.60% Rel Volume0.53 Prev Close79.17
ShortableYes LT Debt/Eq0.33 EarningsNov 05 AMC Payout0.00% Avg Volume2.37M Price77.53
Recom2.20 SMA20-0.24% SMA50-3.11% SMA200-17.98% Volume1,257,613 Change-2.07%
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
Oct-24-20 03:00PM  
Oct-23-20 11:00PM  
10:50PM  
04:55PM  
04:20PM  
01:28PM  
12:00PM  
06:20AM  
Oct-22-20 10:50PM  
04:40PM  
04:24PM  
01:10PM  
12:00PM  
08:30AM  
06:20AM  
Oct-21-20 10:50PM  
09:02PM  
07:30PM  
06:38PM  
06:29PM  
05:00PM  
01:40PM  
01:00PM  
12:33PM  
12:20PM  
12:00PM  
07:30AM  
06:20AM  
Oct-20-20 10:50PM  
09:30PM  
08:45PM  
06:30AM  
Oct-19-20 10:50PM  
10:00PM  
09:15PM  
01:30PM  
01:00PM  
06:30AM  
Oct-17-20 07:45PM  
06:22PM  
Oct-16-20 06:30AM  
Oct-15-20 10:50PM  
05:10PM  
04:45PM  
03:00PM  
02:00PM  
12:00PM  
11:45AM  
11:30AM  
11:20AM  
06:30AM  
Oct-14-20 10:50PM  
10:15PM  
06:25PM  
06:00PM  
09:27AM  
08:00AM  
06:20AM  
Oct-13-20 10:50PM  
10:35PM  
09:45PM  
09:40PM  
07:16PM  
06:20AM  
Oct-12-20 11:07PM  
10:50PM  
05:25PM  
04:00PM  
Oct-11-20 10:35AM  
Oct-10-20 03:00PM  
Oct-09-20 10:50PM  
06:20AM  
Oct-08-20 11:52PM  
10:50PM  
04:40PM  
04:10PM  
01:08PM  
11:45AM  
11:00AM  
10:00AM  
07:13AM  
06:20AM  
Oct-07-20 10:50PM  
08:30PM  
08:00PM  
11:50AM  
11:00AM  
08:31AM  
06:20AM  
Oct-06-20 10:50PM  
09:45PM  
06:45PM  
03:49PM  
01:15PM  
12:47PM  
11:00AM  
09:00AM  
08:00AM  
06:07AM  
Oct-05-20 10:50PM  
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 14Sale79.912,121169,48961,281Oct 15 07:17 PM
HERON ELAINE JDirectorOct 07Option Exercise26.4915,000397,35066,968Oct 08 08:35 PM
PYOTT DAVID E IDirectorAug 31Buy78.2612,8001,001,71530,740Sep 01 09:44 PM
GREY MICHAEL GDirectorAug 03Option Exercise26.492,50066,22545,340Aug 05 06:56 PM
GREY MICHAEL GDirectorAug 03Sale120.352,500300,87542,840Aug 05 06:56 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Option Exercise65.97126,3898,337,656229,384Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Sale130.00126,38916,430,570102,995Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Option Exercise65.9723,0111,518,094126,006Jul 15 09:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Sale130.0023,0112,991,430102,995Jul 15 09:32 PM
Dere Willard HDirectorJun 26Sale123.614,430547,59213,290Jun 30 02:11 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Option Exercise63.1015,000946,50078,402Jun 23 07:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Sale124.0015,0001,860,00063,402Jun 23 07:24 PM
LAWLIS V BRYANDirectorJun 05Sale107.464,430476,04818,850Jun 09 06:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise21.5120,000430,200318,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale91.7220,0001,834,400298,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Option Exercise21.515,000107,550303,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Sale88.005,000440,000298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise21.514,00086,040302,552May 05 07:22 PM
Davis George EricEVP, General CounselMay 01Sale89.3812,5041,117,60865,677May 04 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale89.384,000357,520298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Sale97.5820,0001,951,600298,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale97.7320,0001,954,600298,213Apr 29 07:40 PM
FUCHS HENRY JPresident, Worldwide R&DApr 24Sale95.8820,0001,917,617102,656Apr 28 02:37 PM
FUCHS HENRY JPresident, Worldwide R&DApr 20Sale90.0017,2131,549,170122,656Apr 22 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Option Exercise21.5110,000215,100308,213Apr 13 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Sale79.0610,000790,600298,213Apr 13 06:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale79.982,407192,51263,064Apr 09 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 07Option Exercise26.491,00026,490298,213Apr 08 08:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 01Sale82.001,537126,03465,471Apr 02 08:39 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 25Sale78.471,618126,96467,008Mar 26 08:34 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale74.362,041151,76968,626Mar 26 08:34 PM
LAWLIS V BRYANDirectorMar 17Option Exercise21.513,75080,66322,730Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 17Sale75.393,750282,71318,980Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 16Sale76.524,610352,75718,980Mar 18 08:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise21.5110,000215,100306,443Mar 11 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale89.5210,000895,200296,443Mar 11 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Option Exercise21.5110,000215,100338,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Sale83.5010,000835,000328,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 30Option Exercise21.511,00021,510328,530Feb 03 07:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise21.518,000172,080335,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale87.958,000703,600327,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise21.514,00086,040331,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale84.924,000339,680327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise21.513,00064,530330,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale84.463,000253,380327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Option Exercise21.515,000107,550332,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Sale86.165,000430,800327,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise21.513,00064,530330,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale86.433,000259,290327,530Dec 30 07:27 PM
LAWLIS V BRYANDirectorDec 17Option Exercise21.513,75080,66327,340Dec 19 08:09 PM
LAWLIS V BRYANDirectorDec 17Sale83.363,750312,60023,590Dec 19 08:09 PM
Davis George EricEVP, General CounselNov 26Sale79.663,190254,11568,709Nov 27 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise21.5110,000215,100337,080Nov 26 01:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale77.6010,000776,000327,080Nov 26 01:34 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.